Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284936 | 1.00 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL10227270 | 1.00 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL14049361 | 0.97 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL14438724 | 0.96 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL14453529 | 0.94 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL16297890 | 0.90 | ADRB3 (0.59) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL10227190 | 0.90 | ADRB3 (0.59) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL10227347 | 0.88 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL5155411 | 0.86 | ADRB3 (0.58) | ADRB3ADRA2BADRA2CCTSBPPP3CB | |
| SCHEMBL5153095 | 0.86 | ADRB3 (0.58) | ADRB3ADRA2BADRA2CCTSBPPP3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7442695-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442695-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | SCHERING CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | SCHERING CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-7253160-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253160-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | DPP3, DPP7, DPP4 | ADRB3 3738/4885ADRA2B 4407/4885ADRA2C 4161/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | ADRB3 4070/4885ADRA2B 4543/4885ADRA2C 4304/4885 |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | LPXN, SLC5A11, F12 | ADRB3 535/4885ADRA2B 457/4885ADRA2C 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.